Home/ Peptides/ Kisspeptin

Back to all peptides

Kisspeptin

Kisspeptin is the master regulator of human reproductive biology. A naturally occurring neuropeptide family that signals your pituitary to release the hormones that govern fertility, libido, and long-term endocrine health. At Paragon, we work with it the way we work with every tool in the Paragon Method. Carefully, with your physiology in view, and only when the data says it is the right fit for you.

Important status notice. Kisspeptin is a research peptide. It is not FDA approved for the indications discussed on this page. Any use at Paragon is under direct physician supervision as part of an individualized plan. Kisspeptin is also on the World Anti-Doping Agency (WADA) Prohibited List under S2 (Peptide Hormones and Related Substances). If you compete in a WADA-regulated sport, this protocol is not appropriate for you. Talk to your physician and your sport governing body before considering it.

Book a Consultation

Overview

Kisspeptin sits at the top of the reproductive axis. When your brain releases it, your hypothalamus releases GnRH, your pituitary releases LH and FSH, and your gonads produce testosterone or estrogen in response. It is the switch that turns the whole cascade on.

That position matters. Most hormone therapies act downstream, replacing the hormones your body has stopped making. Kisspeptin works further up the chain. It asks your own system to respond, rather than bypassing it.

We use it with patients whose labs point to a functional issue. Low testosterone with preserved pituitary capacity. Hypothalamic amenorrhea. Fertility work. Libido complaints that track with endocrine signals rather than lifestyle or relationship factors. It is a precision tool. It is not a general wellness add-on.

CHEMICAL STRUCTURE & PROPERTIES

  • Molecular Formula (KP-54): C₂₅₈H₄₀₁N₇₉O₇₈
  • Molecular Weight (KP-54): 5,857.41 Daltons
  • Sequence (KP-10): Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH₂
  • Conserved Motif: C-terminal RFamide (Arg-Phe-NH₂)
  • CAS Number (KP-10): 374675-21-5
  • Half-life (KP-54): Approximately 28 minutes in plasma following IV administration
  • Half-life (KP-10): Approximately 1.7 minutes in plasma (preclinical models)
  • Stability: Lyophilised powder; store at 2°C to 8°C before reconstitution

Mechanism of Action

The Reproductive Axis

  • Kisspeptin is released by the hypothalamus and binds to KNDy neurons
  • Binding triggers GnRH (gonadotropin-releasing hormone) secretion
  • GnRH signals the pituitary to release LH (luteinizing hormone) and FSH (follicle-stimulating hormone)
  • LH and FSH act on the gonads to stimulate testosterone or estrogen production

Upstream vs. Downstream Action

  • Most hormone therapies replace hormones the body has stopped producing
  • Kisspeptin operates further up the chain, stimulating the body's own production cascade
  • The pituitary capacity must be intact for kisspeptin to produce a response
  • This mechanism preserves the body's natural feedback loop rather than bypassing it

Fertility and Ovulation

  • Kisspeptin plays a central role in the LH surge that triggers ovulation
  • It has been studied as a tool for ovulation induction in women with hypothalamic amenorrhea
  • Its pulsatile signaling pattern mirrors the body's natural GnRH release rhythm
  • Research has shown effects on brain regions associated with sexual attraction and arousal

Libido and Neuroendocrine Effects

  • Early research has demonstrated kisspeptin activity in brain regions linked to attraction and arousal
  • Its effects on libido appear to track with endocrine signaling rather than psychological factors
  • This distinguishes kisspeptin-related libido concerns from relationship or lifestyle contributors
  • Response in this domain varies by individual and is assessed alongside lab work and subjective markers

Clinical Applications and

Research Evidence

Low Testosterone and Hormone Health

Primary Investigation: Kisspeptin can stimulate LH release and raise testosterone in a pattern that more closely resembles natural secretion.

  • Studies in men with low testosterone have shown kisspeptin-driven LH release
  • Testosterone elevations in these studies followed physiologic secretion patterns
  • The pituitary must retain functional capacity for this mechanism to work
  • This approach is considered for patients who want a more physiologic option than direct hormone replacement

Mechanism: Kisspeptin binds to hypothalamic receptors and drives GnRH release, which signals the pituitary to produce LH, which in turn stimulates testicular testosterone production — the body's own cascade, not a bypass of it.

Fertility and Hypothalamic Amenorrhea

Emerging Applications: Studies in women have demonstrated a role for kisspeptin in ovulation induction.

  • Kisspeptin has been used in research settings to trigger ovulation in women with hypothalamic amenorrhea
  • It targets the central (brain-level) cause rather than acting directly on the ovaries
  • Hypothalamic amenorrhea — often linked to stress, under-fueling, or excessive training — responds to kisspeptin's upstream signal
  • Fertility applications are managed in coordination with clinician goals and monitoring

Mechanism: Kisspeptin restores the GnRH pulse that drives LH surge and ovulation, addressing the source of the hormonal disruption rather than substituting end-stage hormones.

Libido and Sexual Response

Research Potential: Early work on sexual response has shown effects on brain regions linked to attraction and arousal.

  • Persistent low libido that tracks with endocrine signals rather than lifestyle or relationship factors is a candidate application
  • Research has identified kisspeptin activity in brain regions associated with sexual attraction and motivation
  • This is a distinct mechanism from psychological or relational contributors to libido concerns
  • Clinical use in this area is supported by lab work, not assumed from symptoms alone

Mechanism: Kisspeptin's neuroendocrine signaling extends beyond reproductive hormone production into areas of the brain involved in sexual motivation and arousal, offering a potential biologic explanation for hormonally driven libido complaints.

Current Clinical Evidence

Safety Considerations

Clinical Safety Data

Kisspeptin has a reasonable short-term safety profile in the published studies. Reported side effects are generally mild and may include:

  • Injection site reactions
  • Transient headache
  • Mild nausea
  • Hormonal shifts you may feel because the mechanism is working

Monitoring and Response

Because kisspeptin acts on the reproductive axis, it can shift hormone levels in ways you will feel. That is the mechanism working. It also means we monitor closely.

  • Labs are re-checked on a schedule that matches your protocol
  • Subjective markers are tracked alongside numbers: energy, sleep, libido, cycle regularity, mood
  • If at any point your response is not what we expect, we adjust or stop

Considerations

  • Long-term safety data is limited; we discuss this with you before you begin
  • Individual responses vary — we set expectations specific to your physiology, not a template
  • Potential interactions with other hormonal medications require review during intake
  • Kisspeptin is not appropriate for self-prescribing; it acts at the pituitary level

Contraindications

Kisspeptin should not be used in:

  • Patients with hormone-sensitive cancer or a personal or family history that raises that concern
  • Pregnancy or nursing outside a fertility-guided clinical plan
  • Anyone competing in a WADA-regulated sport at any level
  • Patients whose labs or history suggest it is not a good match, as determined by a qualified clinician

Regulatory Status and

Legal Considerations

Global Regulatory Status

No Approved Medical Use:
  • Not FDA approved for the indications discussed on this page
  • No regulatory approval from any major health authority for the uses described here
  • Classified as a research peptide; any use at Paragon is under direct physician supervision

WADA Anti-Doping Status

Prohibited Substance Classification:
  • Category: S2 — Peptide Hormones and Related Substances (prohibited at all times)
  • Rationale: Classification as a peptide hormone affecting the reproductive axis
  • Athletic Use: Banned in all WADA-regulated competitive sports
  • Detection: Urine and blood testing available for anti-doping purposes

Legal Availability

Research and Clinical Use:
  • Research use of kisspeptin is legal in the United States
  • Any use at Paragon is part of an individualized, physician-supervised plan
  • Compounding source, quality, and chain of custody are reviewed during consultation
  • Not appropriate for self-prescribing or use outside a supervised clinical context

Administration and Dosing

Considerations

Reconstitution and Administration:

  • Kisspeptin is administered by subcutaneous injection
  • Specific dose, timing, and cycle length are determined by your clinician based on your labs and goals
  • We do not publish a standard protocol on this page — dosing for fertility is not the same as dosing for libido or low testosterone
  • Sharing a one-size number invites people to self-prescribe, and self-prescribing with a pituitary-level signaling peptide is the wrong move

Clinical Considerations:

  • No established one-size protocol exists; all dosing is individualized
  • During your consultation, you will receive a written protocol, a review of what to expect, and a direct point of contact
  • Professional oversight required throughout the protocol period
  • Response varies significantly between individuals; your clinician will set expectations specific to your plan

How Soon Will I Feel a Difference:

  • It depends on what you are working on
  • Some patients notice shifts in libido or mood within the first cycle
  • Hormone level changes on labs typically show up within two to six weeks
  • Fertility outcomes have their own timeline
  • Your clinician will set expectations specific to your plan

Combinations and Stacking:

  • Kisspeptin can sometimes be combined with other peptides or treatments
  • Every combination is a clinical decision, not a catalog choice
  • We will not stack protocols that create unnecessary risk or blur the signal on what is actually working
  • Combinations are reviewed as part of your full intake, not added on request

Conclusion

See whether kisspeptin fits your physiology.

At Paragon, every plan begins with a commitment to understanding the whole picture of your health. That means starting with a comprehensive intake, reviewing your current labs, and having a thoughtful conversation about what you truly want to change not just surface-level goals, but the deeper outcomes that matter to you. From there, we evaluate the tools available. Kisspeptin may be one of them, but it is never assumed. If it aligns with your physiology and supports the changes you’re aiming for, we will recommend it with clarity and confidence. If it does not, we will be equally direct, guiding you toward alternatives that better suit your biology and long-term objectives.

Our role is not to push a single solution, but to help you navigate the complexity of human physiology with honesty and precision. Every recommendation is grounded in evidence, tailored to your unique profile, and designed to move you closer to the future you envision for yourself.

Book a consultation
Book a consultation

KISSPEPTIN SCIENTIFIC

DATA SUMMARY

Parameter
Value
Gene / Chromosome
KISS1 — chromosome 1q32, 4 exons
Precursor Protein
145 amino acids (kisspeptin-145)
Active Isoforms
Kp-54 (major circulating form), Kp-14, Kp-13, Kp-10 — all share C-terminal RFamide motif essential for receptor binding
Receptor
KISS1R (formerly GPR54 / AXOR12) — Gq/11-coupled GPCR; activates PLC → Ca²⁺ mobilisation
Plasma Half-Life
Kp-54: ~28 minutes | Kp-10: ~4 minutes
Bioavailability / Route
IV and subcutaneous injection only — oral bioavailability is negligible due to rapid enzymatic degradation
Inactivation
C-terminal cleavage by MMP-2/9 renders peptide inactive
System
Function
Reproductive Axis (HPG)
Master upstream regulator of pulsatile GnRH secretion from hypothalamus → drives LH/FSH release from anterior pituitary
Puberty Onset
Critical initiator; loss-of-function KISS1R mutations → idiopathic hypogonadotropic hypogonadism (IHH) and failure of puberty in humans and rodents
Ovulatory LH Surge
Mediates estrogen-induced preovulatory GnRH/LH surge; driven by arcuate nucleus (ARC) and AVPV kisspeptin neuron populations
Metabolic Integration
Links energy status to fertility; Kiss1 mRNA in ARC suppressed by negative energy balance and leptin deficiency; ghrelin acts counter to kisspeptin signalling
Tumor / Metastasis Suppression
Original "metastin" discovery (1996, Welch lab, Penn State); suppresses melanoma and breast cancer metastasis without affecting primary tumour growth
Psychosexual Processing
Activates limbic regions associated with sexual arousal and attraction; modulates reward and emotional brain processing independently of hormonal effects
Placentation
High KISS1R expression in placenta; regulates trophoblast invasion and normal placental development
Application
Model
Dose / Route
Outcome
GnRH / LH Stimulation
Rodents, sheep, primates
nmol/kg IV or ICV
Robust dose-dependent LH surges; continuous infusion suppresses via receptor desensitisation — pulsatile delivery required
Ovulation Induction
Sheep, rat, primate
Pulsatile SC / ICV
Restored ovulatory cycles; intermittent Kp-10 induced precocious puberty in pre-pubertal primates
Metastasis Suppression
Melanoma, breast cancer (mouse)
Systemic injection
Significant reduction in metastatic spread; KISS1 transfection suppressed metastasis without cytotoxicity
Placentation
Murine pregnancy model
Various
Regulates trophoblast invasion; critical for normal placental development
Metabolic / Endocrine
Rodents
Various
KISS1R expressed in pancreas, liver, and adipose tissue; links to insulin secretion and glucose metabolism under investigation
Study
Population
Results
Notes
Dhillo et al. 2005
Healthy men
Dose-dependent LH, FSH and testosterone rise at 0.4–12.8 nmol/kg IV
First human kisspeptin trial; Imperial College London
Jayasena et al. 2009
Women with hypothalamic amenorrhea (HA)
Acute SC dose stimulated gonadotropins; chronic twice-daily dosing caused tachyphylaxis by day 14; twice-weekly dosing showed lower desensitisation
Established pulsatile dosing requirement
Jayasena & Abbara et al. 2014
53 women undergoing IVF (superovulated)
Successful oocyte maturation, fertilisation, embryo transfer and confirmed live human pregnancy
Landmark proof-of-concept; J Clin Invest 2014
Abbara et al. 2015
Women at high risk of OHSS during IVF
Successful oocyte maturation with markedly reduced OHSS risk vs hCG trigger; near-elimination of moderate OHSS in Phase 2 data
J Clin Endocrinol Metab 2015
Jayasena et al. 2014 — Pulsatile
Women with hypothalamic amenorrhea
Restored LH pulsatility; follicular development observed during infusion
J Clin Endocrinol Metab 2014
Comninos et al. 2017
Healthy men
Enhanced limbic brain response to sexual stimuli; increased erection frequency vs placebo; effects independent of hormonal changes
J Clin Invest 2017; single-centre, small N
Parameter
Finding
Acute Tolerability
Well tolerated across all published Phase I/II trials; no serious adverse events reported
Tachyphylaxis
Continuous or twice-daily SC dosing leads to receptor desensitisation within days via clathrin-mediated internalisation of KISS1R and β-arrestin; twice-weekly dosing produces lower desensitisation. Pulsatile delivery required for sustained HPG axis stimulation
OHSS Risk (IVF)
Significantly lower than hCG trigger; Kp-54 produces a shorter, more physiological LH surge (peak ~4.7 hrs) compared to hCG (~36 hr half-life)
Oncologic Risk
No tumour-promoting effects in any clinical data; KISS1R signalling is suppressive to metastasis
Long-term Safety
No long-term data beyond short-term trials (most studies: days to weeks); no large Phase 3 RCT data available
Evidence Base Limitation
Majority of human clinical data from two centres: Imperial College London (Dhillo, Abbara, Comninos) and Massachusetts General Hospital (Seminara, Chan). Independent replication is limited
Regulatory Status (FDA)
Investigational Compound — no approved indication; active IND studies ongoing in reproductive endocrinology
Regulatory Status (EMA)
Investigational — Phase II trials ongoing; no approved indication
Regulatory Status (WADA)
S2 — Peptide Hormones / Testosterone-Stimulating Peptides; explicitly prohibited in males both in- and out-of-competition as of January 2024

Disclaimer: This information is provided for educational and research purposes only and does not constitute medical advice. Kisspeptin is not approved by the FDA, EMA, or any major regulatory authority for therapeutic use. All clinical data referenced herein is drawn from published peer-reviewed research. Kisspeptin is explicitly listed on the WADA Prohibited List under category S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) effective January 2024 and is prohibited in males both in- and out-of-competition. Athletes must not use kisspeptin in any competitive sport context. Patients and researchers should consult with qualified healthcare providers and ensure compliance with applicable regulations before considering any use of kisspeptin.